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BACKGROUND: The cytodiagnosis of melanoma in fine-needle aspiration (FNA) specimens can be chal-
lenging, often requiring the use of immunocytochemistry. As constitutively activating mutations in the
BRAF oncogene are present in at least 40% of melanomas, the use of FNA material to interrogate the
BRAF mutational status is likely to increase. Because cell blocks, traditionally used for these studies, can
occasionally exhibit insufficient tumor cellularity, the authors investigated the utility of direct smears for
immunocytochemistry and BRAF mutational analysis. METHODS: Immunocytochemistry for S-100, HMB-45,
and Mart-1 was prospectively performed on direct smears in 17 FNAs of metastatic melanoma. Next, BRAF
sequencing was performed using DNA isolated from archived Diff-Quik–stained direct smears for 15 cases.
In parallel, sequencing was performed using DNA obtained from corresponding cell blocks. RESULTS: S-
100 positivity in the tumor cells was observed in all 17 cases. HMB-45 and Mart-1 positivity was noted in
81% and 88% of cases, respectively. All 3 markers were positive in 76% of cases. Next, of the 15 archived
melanoma FNAs tested, BRAF mutations were observed in 8 (53%); 5 and 3 melanomas harbored the
V600E and V600K mutation, respectively. Corresponding cell blocks were also tested for all 15 cases, yield-
ing concordant BRAF results in 14 (93%); 1 cell block yielded a false-negative result. CONCLUSIONS: Cyto-
logic direct smears represent a robust and valuable source of cellular material for immunocytochemistry
and molecular studies, especially in instances in which inadequate cell block cellularity is anticipated or
encountered. Cancer (Cancer Cytopathol) 2012;120:52–61. VC 2011 American Cancer Society.
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In 2010, it is estimated that >68,000 men and women were diagnosed with melanoma and 8700 died of
the disease.1 The morbidity and mortality associated with melanoma stems from a multitude of factors
including challenges in establishing a diagnosis, limited understanding of the molecular pathogenesis
underlying the disease, unpredictable presentation of metastatic foci, and limited treatment options for
those with advanced disease.2,3 Surgical therapy is more effective in patients with localized or early mela-
noma; however, melanoma that has spread to locoregional lymph nodes or distant sites is largely refractory
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to currently available systemic therapies such as high-dose
interferon, dacarbazine, temozolomide, and high-dose
interleukin-2; the survival advantage offered by these
agents is marginal.2
Fine-needle aspiration (FNA) represents a mini-
mally invasive technique and an accurate, safe, and afford-
able means to achieve a tissue diagnosis. FNA is therefore
becoming an increasingly used modality to establish a di-
agnosis of metastatic melanoma.3-6 An early definitive di-
agnosis of metastatic melanoma can facilitate prompt,
appropriate management including surgical removal or
avoidance of unnecessary surgery and accurate staging of
patients in clinical trials.6
Because melanoma can exhibit a variety of cytomor-
phologic features and mimic other neoplasms such as car-
cinomas and sarcomas, identifying melanoma in aspirates
and distinguishing it from its mimics can occasionally be
challenging.7-9 The presence of melanin pigment can be
helpful in the cytodiagnosis of melanoma; nonetheless,
amelanotic melanomas are commonly encountered in
FNAs. Specifically, through their analysis of a large series
of melanoma FNAs, Saqi et al9 discovered that 68% of
melanoma specimens failed to demonstrate any identifia-
ble intracytoplasmic melanin pigment. Hence, cytopatho-
logists can potentially face difficult scenarios in which a
melanoma must be accurately distinguished from benign,
reactive processes and from other malignant entities based
on limited material. Immunocytochemistry is commonly
used to confirm a diagnosis of melanoma in FNA speci-
mens.8,10-13 Common markers used in this regard are
antibodies directed against S-100, HMB-45, and Mart-1/
Melan-A.
In addition, the lack in understanding of signature
genetic aberrations associated with melanoma has con-
founded the ability for targeted therapy for metastatic
melanoma. However, the recent discovery that constitu-
tively activating mutations in the BRAF oncogene are
present in at least 40% of melanomas has created strategic
opportunities for targeted therapeutics.2,14,15 The V600E
and V600K substitutions represent the 2 most common
BRAF mutations in melanoma.16 Clinical trials are cur-
rently being performed to assess the efficacy of BRAF
inhibitors in the treatment of melanoma. Recently, Flah-
erty et al2 reported that in patients with melanomas har-
boring the BRAF V600E mutation, therapy with
PLX4032 results in partial tumor regression in the major-
ity of cases. Another report by Rubinstein et al17 suggests
that melanomas harboring the V600K mutation could
also respond to PLX4032.
Routinely, immunocytochemical and molecular an-
cillary studies have used cell blocks prepared from mela-
noma FNAs. Occasionally, insufficient cellularity of the
cell blocks can be a problematic issue, thereby impeding
the performance of these assays. This can lead to repeat
procedures to obtain additional cellular material, which
are not without potential complications. Given the inher-
ent unpredictability of cell block cellularity and the
increased need to interrogate the immunophenotype and
BRAFmutation status of melanoma FNAs, the purpose of
this study was 2-fold. We first sought to prospectively
investigate the application of immunocytochemistry for
S-100, HMB-45, and Mart-1 to cytologic direct smears.
We then extended our analysis by demonstrating that
BRAF mutation testing can be effectively performed on
Diff-Quik–stained cytologic smears.
MATERIALS AND METHODS
This study was approved by the Institutional Review
Board at the University of Michigan. First, 17 consecutive
cases of metastatic melanoma were prospectively eval-
uated in which unstained direct smears were prepared,
using positively charged slides, for confirmatory immuno-
cytochemistry. Immunocytochemistry was performed on
air-dried, unstained direct smears after fixation in forma-
lin for 30 minutes using the Ventana Autostainer (Ven-
tana Medical Systems, Tucson, Ariz) as performed
previously.18 Incubation with a rabbit polyclonal anti-
body directed against S-100 (prediluted; VentanaMedical
Systems) was performed for 24 minutes without pretreat-
ment. Incubation with mouse monoclonal antibodies
against HMB-45 (prediluted; Dako, Carpenteria, Calif)
and Mart-1 (clone A103, prediluted; Ventana Medical
Systems) were performed for 16 minutes and 20 minutes
after antigen retrieval with CC1 buffer (pH 8.5) at 95C
for 8 minutes and 36 minutes, respectively. Positive and
negative controls were performed in parallel. Negative
controls were performed on unstained direct smears. Posi-
tive controls were performed using formalin-fixed, paraf-
fin-embedded sections of melanoma. Furthermore, for
comparison, cell block sections were used for immunohis-
tochemistry when tumor cells were present in the cell
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block (14 of 17 cases). The cell blocks in 3 cases were acel-
lular, precluding comparative immunohistochemistry.
Sixteen cases of metastatic melanoma were amelanotic
and 3,30-diaminobenzidine (DAB) was used as the
chromogen. In the remaining case, abundant melanin pig-
ment was present; hence, immunostaining using alkaline
phosphatase was used. Cytoplasmic and/or nuclear stain-
ing for S-100 and cytoplasmic staining for HMB-45 and
Mart-1 were scored semiquantitatively by 3 cytopatholog-
ists (K.H., M.H.R., and S.M.K.) using a 3-tier scoring
system in which 0 represented negative staining and 1þ,
2þ, and 3þ corresponded to immunoreactivity in <
10%, 10% to 50%, and > 50% of the tumor cells,
respectively.
Next, air-dried, Diff-Quik–stained smears from 15
consecutive FNAs of metastatic melanoma (performed
between January 2010 and July 2010) in which at least 2
Diff-Quik–stained smears with abundant diagnostic ma-
terial were present were retrieved from the archive and
selected for BRAF mutation testing. Diff-Quik–stained
smears (1 slide per case) were incubated in xylene for 1
week. After the coverslips were gently removed, the slides
were allowed to dry, reviewed by 2 cytopathologists (K.H.
and M.H.R.), and the area most enriched in tumor cells
was marked on the underside of each slide using a mark-
ing pen. The size of the selected area (in mm2) and the
percentage of tumor cells within the area were recorded.
In addition, the corresponding cytologic cell block was
retrieved for each case for parallel BRAFmutation testing.
The cellularity of each cell block was semiquantitatively
assessed by evaluating the original hematoxylin and eosin
(H& E)-stained cell block sections as follows: 0, acellular;
1þ, sparse cellularity; 2þ, moderate cellularity; and 3þ,
abundant cellularity. The estimated percentage of tumor
cells was also recorded for each cell block section.
For the Diff-Quik–stained direct smears, genomic
DNA was extracted from the marked region using the Pin-
point Slide DNA Isolation Kit (Zymo Research Corpora-
tion, Orange, Calif) as per the manufacturer’s instructions
and including the optional purification step. Briefly, Pin-
point Solution was applied to the designated area of each
slide to be extracted and allowed to air dry into a thin film.
The film was then gently lifted and transferred to a 1.5-mL
microcentrifuge tube, and 50 lL of 1-step Extraction
Buffer containing proteinase K was added and incubated
at 55C for 4 hours, followed by incubation at 95C for
10 minutes. An optional DNA cleanup step was per-
formed for each sample by adding 100 lL of Pinpoint
Binding Buffer to each proteinase K-treated DNA sample
and then transferring the solution to a supplied spin col-
umn. The spin column was microcentrifuged for 10 sec-
onds at 14,000g and washed twice with Pinpoint Wash
Buffer with microcentrifugation between washes, followed
by a final centrifugation step (14,000g for 1 minute).
DNA was eluted in a final volume of 25 lL of TE buffer
(10 mM of Tris-HCl and 0.5 mM of ethylenediamine tet-
raacetic acid [EDTA] [pH 9.0]). For paraffin-embedded
cytology cell blocks, genomic DNA was extracted on the
BioRobot EZ1 (Qiagen, Chatsworth, Calif) using the par-
affin section protocol. For each block, 5 sections meas-
uring 10 lm in thickness were used for extraction. DNA
was eluted in a final volume of 100 lL of TE buffer.
BRAF mutation status was evaluated by direct
sequencing. A 204-base pair fragment containing BRAF
exon 15 was amplified using the following primer pairs:
50TGCTTGCTCTGATAGGAAAATG30 (forward) and
50TCAGTGGAAAAATAGCCTCAATTC30 (reverse).
Each 30-lL polymerase chain reaction (PCR) contained 5
lL of purified DNA, 300 nM of each primer, and 1 
Phusion HF mastermix (Finnzymes Thermo Scientific,
Pittsburgh, Pa). Cycling conditions were comprised of
denaturation at 98C for 30 seconds followed by 40
amplification cycles: 99C for 5 seconds, 60C for 20 sec-
onds, and 72C for 20 seconds. An aliquot of each PCR
product was confirmed by gel electrophoresis. The re-
mainder was purified by the QIAquick PCR purification
kit (Qiagen) and subjected to bidirectional sequencing
with ABI BigDye v1.1 terminators and the following
nested sequencing primers: 50TTTACTTACTACACCT
CAGATAT30 (forward) and 50GGAAAAATAGCCTCA
ATTCTTACC30 (reverse). Sequence products were puri-
fied using the DyeEx Spin Kit (Qiagen) and analyzed on
the ABI 3130xl genetic analyzer (Applied Biosystems,
Bedford, Mass). Both forward and reverse sequence chro-
matograms were reviewed for mutations with software-
assisted analysis (Mutation Surveyor, SoftGenetics, St.
College, Pa).
RESULTS
Immunocytochemistry for S-100, HMB-45, and Mart-1
was prospectively performed on unstained, air-dried
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direct smears for 17 FNAs of metastatic melanoma. All
the patients had a history of melanoma. The FNA sites
and the results of immunocytochemistry are summarized
in Table 1. No significant intracytoplasmic melanin pig-
ment was appreciated in the tumor cells in 16 of the 17
cases. In all 17 cases, immunoreactivity of the tumor cells
for S-100 was observed;> 50% of the tumor cells were S-
100 positive (þ) in 15 of 17 cases and focal (1þ) and
moderate (2þ) positivity was noted in the remaining 2
cases (Table 1). Next, immunocytochemistry for HMB-
45 was performed in 16 of the 17 cases in our cohort; in
13 (81%) of these 16 cases, immunoreactivity of the tu-
mor cells for HMB-45 was observed. Greater than 50% of
the tumor cells were HMB-45(þ) in 6 cases. In 5 cases,
between 10% and 50% of the tumor cells were HMB-
45(þ). In 2 cases, focal staining of the tumor cells (<
10%) was observed (Table 1, cases 7 and 16). Fifteen
(88%) of the 17 cases of metastatic melanoma exhibited
immunoreactivity of the tumor cells for Mart-1. In 13
cases, > 50% of the tumor cells were immunoreactive for
Mart-1. In 2 cases,< 50% of the tumor cells were immu-
noreactive for Mart-1 (Table 1, cases 1 and 6). Overall,
immunoreactivity for all 3 melanoma markers was
observed in 13 (76%) of 17 cases of metastatic melanoma.
One case was notable for the sparsity of tumor cells in the
background of polymorphous lymphocytes (Table 1, case
2). Virtually all of the tumor cells were positive for S-100,
HMB-45, and Mart-1 (Fig. 1). Two cases exhibited an S-
100(þ)/HMB-45 negative ()/Mart-1() immunophe-
notype and 1 case displayed an S-100(þ)/HMB-45()/
Mart-1(þ) immunoprofile (Fig. 1). Immunohistochemis-
try was also performed using cell block sections in 14 of
17 cases; the immunophenotype of the tumor cells was
identical to that observed on the direct smears in all 14
cases. Immunohistochemistry could not be performed in
the remaining 3 cases due to acellularity of the cell block
preparations.
Next, we analyzed cases of metastatic melanoma,
using cellular material derived from Diff-Quik–stained
smears, for the presence or absence of mutations in BRAF.
For this purpose, smears from 15 cases were retrieved
from the archive and the coverslips removed. Subse-
quently, tumor-enriched areas were microdissected from
each smear; the microdissected areas ranged from 24 mm2
to 56 mm2 (Fig. 2). The percentage tumor cellularity
within these enriched areas was at least 70% for all cases
and was> 90% in 11 of 15 cases (Table 2). DNA of high
quality and purity was obtained in each case. Overall, a
mutation in BRAF was observed in 8 (53%) of the 15 mel-
anomas tested. Specifically, the V600E mutation was
Table 1. Immunocytochemistry on Direct Smears of Metastatic Melanoma
Case No. FNA Site Results of
Immunocytochemistry
a
S-100 HMB-45 Mart-1
1 Left groin 3þ NP 1þ
2 Left neck 3þ 3þ 3þ
3 Right groin 3þ 2þ 3þ
4 Right axillary lymph node 3þ 3þ 3þ
5 Right chest 3þ 2þ 3þ
6 Left shoulder 3þ 0 2þ
7 Right posterior thigh 3þ 1þ 3þ
8 Subcarinal lymph node 3þ 3þ 3þ
9 Right dorsal foot 3þ 2þ 3þ
10 Left chest 3þ 0 0
11 Left neck 1þ 0 0
12 Left neck 3þ 3þ 3þ
13 Right hilar lymph node 3þ 3þ 3þ
14 Right supraclavicular lymph node 2þ 2þ 3þ
15 Right axillary lymph node 3þ 3þ 3þ
16 Left inguinal lymph node 3þ 1þ 3þ
17 Subcarinal lymph node 3þ 2þ 3þ
Abbreviations: FNA, fine-needle aspiration; NP, not performed.
a A score of 0 denotes negative staining in all of the tumor cells. Scores of 1þ, 2þ, and 3þ denote immunoreactivity in
<10%, 10% to 50%, and >50% of the tumor cells, respectively.
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detected in 5 (33%) cases and the V600K mutation was
detected in 3 (20%) cases. For comparison, the corre-
sponding cell blocks for each case were also tested in paral-
lel. Seven, 3, and 5 cell blocks exhibited sparse, moderate,
and abundant cellularity, respectively; the percentage tu-
mor cellularity varied from < 10% to > 90% (Table 2).
Concordant sequencing results were observed in 14
(93%) of 15 cases; however, in 1 case (Table 2, case 10),
the mutation was not detected in the cellular material
obtained from the cell block, whereas the V600E muta-
tion was detected in the direct smear (Fig. 3). There were
no cases in which a BRAF mutation was detected in the
cell block material but not in the cellular material from
the smears.
DISCUSSION
Difficulties can be encountered in the diagnosis of mela-
noma on FNA specimens owing to variations in cytomor-
phologic presentation and similarities to other malignant
entities such as metastatic carcinoma and sarcoma.3-5,7-
11,19 An accurate cytodiagnosis allows for timely, appro-
priate staging of patients with this disease and the prompt
formulation of appropriate next steps in management.6 In
this regard, immunocytochemistry serves as an essential
adjunct in the cytodiagnosis of melanoma. Furthermore,
in this era of personalized medicine and evolving targeted
chemotherapeutics, there is an increased need for molecu-
lar characterization of metastatic melanomas. Recently,
this has been exemplified by the detection of activating
BRAF mutations in melanoma and subsequent ongoing
clinical trials attempting to exploit this molecular signa-
ture from a targeted chemotherapeutic standpoint.2,15
Traditionally, cell blocks have represented the pri-
mary means by which additional cellular material is har-
vested for ancillary immunocytochemical and molecular
diagnostic studies. Nonetheless, the absence of sufficient
cellular material can pose a problem in the adequate
workup of melanoma FNAs in some instances. The cell
block cellularity is influenced by several variables
FIGURE 1. Immunocytochemistry is shown for S-100, HMB-45, and Mart-1 on direct smears in 3 cases of metastatic melanoma.
The top row depicts a case in which the tumor cells are sparsely scattered in a background of lymphocytes. These cells are high-
lighted on all 3 immunocytochemical stains in contrast to the background lymphocytes, which are negative for all 3 markers. The
middle and bottom rows illustrate cases of an S-100 positive (þ)/HMB-45 negative ()/Mart-1(þ) and an S-100(þ)/HMB-45()/
Mart-1() melanoma, respectively. The case numbers correspond to those listed in Table 1 (original magnification1000).
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including the cellularity of the lesion being targeted by
FNA, the percentage tumor cellularity in the lesion being
sampled, the precision in targeting the lesion in successive
needle passes, effective sampling of the lesion during dedi-
cated FNA passes for the cell block, and postprocedural
handling of the needle rinse specimen. In addition, the
quantity of tumor cells in the cell block, as assessed by
routine H&E staining of cell block sections, is not imme-
diately known. Dedicated passes for the cell block may
increase the probability that the cell block is of adequate
tumor cellularity; however, it is not possible to ensure the
effectiveness of additional cell block passes at the time of
the FNA procedure. Recognizing the realistic possibility
that cell blocks may provide inadequate material in sce-
narios in which the need for ancillary studies is the great-
est, the aim of this study was 2-fold: 1) to confirm that
diagnostic immunocytochemical stains for S-100, HMB-
45, and Mart-1 can be performed on direct aspirate
smears successfully; and 2) to investigate the use of direct
smears as a source of cellular material for the performance
of BRAFmutational analysis.
With regard to the first objective, we prospectively
performed immunostains for S-100, HMB-45, and Mart-
1 in 17 consecutive FNAs of metastatic melanoma in
FIGURE 2. Cellular material used for BRAF mutational analysis is shown. Three representative cases corresponding to those listed
in Table 2 are shown. The left column depicts the decoverslipped, Diff-Quik–stained direct smears before microdissection (Pre).
Areas enriched in tumor cells were marked on the underside of the slides and the percentage of tumor cells present in each area
is indicated on the upper right corner of each slide. Representative photomicrographs in each of the indicated areas are shown
(original magnification 600). The middle column depicts the smears after microdissection (Post). Representative photomicro-
graphs of the corresponding cell blocks are shown in the right column. The cell blocks in cases 3, 5, and 6 were of sparse, moder-
ate, and abundant cellularity, respectively.
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which unstained, air-dried direct smears were obtained
on-site for immunocytochemistry. We demonstrated that
S-100 was the most sensitive marker because all 17 cases
of metastatic melanoma exhibited immunopositivity of
the tumor cells for this marker. This is in concordance
with previous reports that describe the high sensitivity of
S-100 in detecting melanoma tumor cells.11,20 For exam-
ple, Kapila et al11 examined 19 FNA cases of metastatic
melanoma by S-100 immunocytochemistry and observed
positivity for this marker in all cases. Nonetheless, because
the specificity of S-100 for melanoma is lower compared
with HMB-45 and Mart-1, and can label native lymph
node elements such as sinus macrophages and dendritic
cells, we also examined these latter 2 markers as well.20
We found that 81% and 88% of melanoma FNAs in our
FNA cohort were positive for HMB-45 and Mart-1,
respectively. These results are consistent with the findings
by Zubovits et al20 that compared the relative sensitivities
of these 3 markers. A few prior reports have demonstrated
the utility of direct smears as a platform to perform immu-
nocytochemical stains in the cytodiagnosis of melanoma;
these studies used alcohol-fixed, Papanicolaou-stained
smears that were destained before immunostaining.8,19
However, it has been noted that false-negative results
could be observed in S-100 immunocytochemistry when
alcohol-fixed smears are used.13,19 In the current study,
air-dried direct smears were fixed in formalin before anti-
gen retrieval and immunocytochemistry, thereby closely
Table 2. BRAF Mutational Analysis Using Direct Smears and Corresponding Cell Blocks of Metastatic Melanoma
Case
No.
FNA
Site
Direct Smears Cell Blocks Direct
Smear/Cell
Block
Concordance
Microdissected
Area, mm2
%
Tumor
a
BRAF
Mutation
Status
Overall
Cellularity
b
%
Tumor
BRAF
Mutation
Status
1 Right groin 24 >90% WT 1þ 80%-90% WT Yes
2 Left ear 25 >90% V600K 1þ >90% V600K Yes
3 Left groin 32 >90% V600E 1þ <10% V600E Yes
4 Left ear 30 70%-80% V600K 2þ 30%-40% V600K Yes
5 Left groin 42 >90% V600E 2þ 80%-90% V600E Yes
6 Left groin 56 >90% V600E 3þ >90% V600E Yes
7 Left axilla 32 >90% V600K 1þ 70%-80% V600K Yes
8 Right hilar
lymph node
49 >90% WT 3þ >90% WT Yes
9 Right neck 30 >90% WT 1þ 20%-30% WT Yes
10 Right axilla 25 80%-90% V600E 1þ <10% WT No
11 Subcarinal
lymph node
40 70%-80% WT 3þ 70%-80% WT Yes
12 Mediastinal
lymph node
50 >90% WT 3þ 30%-40% WT Yes
13 Right axilla 40 >90% V600E 2þ >90% V600E Yes
14 Left arm 49 >90% WT 1þ 80%-90% WT Yes
15 Left neck 50 80%-90% WT 3þ 20%-30% WT Yes
Abbreviations: FNA, fine-needle aspiration; WT, wild type.
a Percentage of tumor in the microdissected area on the direct smear.
bCellularity assessment: 0, acellular; 1þ, sparse cellularity; 2þ, moderate cellularity; 3þ, abundant cellularity.
FIGURE 3. Representative sequencing results are shown for
BRAF mutations detected in direct smears and cell blocks.
Three cases harboring BRAF mutations are shown. In cases 3
and 7, the V600E and V600K mutations were detected,
respectively, in DNA isolated from both the direct smears and
cell blocks. In case 10, the V600E mutation was detected in
the material obtained from the direct smear but not the cell
block.
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approximating the conditions of standard immunohisto-
chemical procedures that use sections derived from forma-
lin-fixed tissue. In 14 cases, tumor cells were present in
the cell block, allowing for a comparison of immunophe-
notypes observed on immunostains performed using
direct smears and formalin-fixed, paraffin-embedded cell
block sections. Identical immunophenotypes were
observed in each case, confirming that our protocol for
performing immunocytochemistry on air-dried direct
smears, after formalin fixation, closely approximates the
conditions under which immunohistochemistry on cell
block sections is performed. It is interesting to note that 1
FNA of metastatic melanoma exhibited a paucicellularity
of tumor cells in a background of numerous polymor-
phous lymphocytes (Table 1, case 2). This scenario high-
lights a potential limitation of relying on cell blocks for
immunocytochemical studies. Especially in this case,
ensuring that the tumor cells would be adequately repre-
sented in the cell block during the on-site assessment of
adequacy would be difficult, despite additional dedicated
passes being performed. For this case, the immunostains
for S-100, HMB-45, and Mart-1 selectively highlighted
the sparsely scattered tumor cells in the background
lymphoid milieu. Although not having performed S-100,
HMB-45, and Mart-1 immunocytochemistry on nonme-
lanoma aspirates represents a limitation to the current
study, our results demonstrate the diagnostic utility of
performing immunocytochemistry for these 3 markers in
the diagnosis of melanoma FNAs.
Another key finding in the current study is that the
use of cytologic direct smears proved to be a robust and
reliable methodology for molecular testing. Mutation test-
ing was successfully performed using cellular material
microdissected from archived, Diff-Quik–stained, deco-
verslipped smears. Overall, BRAF mutations were
observed at the expected frequency15 because 53% of the
tumors analyzed in this study harbored mutations in
BRAF. The majority of the mutations resulted in the
V600E substitution and a minority of tumors exhibited
the V600K substitution. This is consistent with prior
observations that the most common BRAF mutation in
melanoma is V600E followed by V600K.16,17 In all but 1
case, BRAF sequencing results using cellular material
obtained from the direct smears yielded results that were
concordant with those obtained from the corresponding
cell blocks. Of note, the 1 discordant case in which a
BRAF mutation was identified in the direct smear but not
the corresponding cell block was due to limited tumor cel-
lularity in the latter. Specifically, the overall cellularity of
the cell block was low, and > 90% of the cells present in
the cell block were comprised of background lymphocytes
(Table 2, case 10). Given the limited ability to microdis-
sect for tumor cells in cell blocks, this case highlights a
potential limitation of cell blocks containing tumor cells
dispersed among background-contaminating benign cells.
Moreover, because cell blocks represent a cumulative,
pooled specimen derived from multiple needle passes,
dilution of the tumor cell population by benign cellular
elements can yield false-negative mutation results due to
the limited analytic sensitivity of many molecular tests.
The advantages of using air-dried, Diff-Quik–stained
smears for molecular testing include the higher quality of
DNA isolated relative to that prepared from formalin-
fixed tissue and the long-term stability of the DNA in
archived smears.21 Most importantly, the Diff-Quik stain-
ing method is quick, inexpensive, and allows for the rapid
verification of tumor cell adequacy. Tumor-enriched areas
can be easily identified andmarked before triaging for mo-
lecular studies. In this regard, our study differs from a
recent study by Sviatoha et al who performed BRAFmuta-
tional analysis on melanoma FNAs.22 In their study, pel-
leted, frozen cellular material from aspirates was used for
molecular testing. In this setting, it is not possible to
enrich for the tumor cell population; hence, if the repre-
sentation of the tumor cell population is low in a particular
aspirate, a false-negative result may be obtained on molec-
ular assays designed to detect mutations. Recently, we
observed that air-dried smears represented a robust source
of cellular material for epidermal growth factor receptor
(EGFR) and KRASmutational analysis of pulmonary non-
small cell lung cancer.23 Our success in performing BRAF
mutational analysis in this study reiterates the utility and
effectiveness of direct smears for molecular assays. Overall,
these findings are fortuitous for cytopathologists who are
responsible for ensuring immediate adequacy assessments
and for triaging cellular material based on examining Diff-
Quik–stained smears on-site.
In the current study, we used decoverslipped smears
as a source of cellular material for molecular analysis.
Although the Diff-Quik staining protocol and the process
of decoverslipping archival smears do not compromise the
quality of the DNA isolated for molecular studies, as
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evidenced by our findings, we realize that the procedure
of removing coverslips can still be time-consuming.
Therefore, to ensure a quicker turnaround time for
obtaining results of mutational analysis, it would be more
convenient for the cytopathologist to anticipate that addi-
tional cellular material will be needed for molecular analy-
sis and to maintain at least 1 air-dried, uncoverslipped
slide at the time of the FNA procedure. Should molecular
testing be requested, this slide can be promptly stained
with Diff-Quik, marked to indicate tumor-enriched areas,
and immediately sent to the molecular diagnostics labora-
tory for mutational analysis.
The current study findings have important implica-
tions for the optimal triage of FNA speciemens for cyto-
diagnosis and molecular analysis. Preparing multiple
unstained direct smears from 1 or more FNA passes
would allow the cytologist to confirm on-site that
adequate material has been obtained not only for cyto-
diagnosis but also for ancillary studies. Specifically, in
addition to the routinely prepared air-dried, Diff-Quik–
stained and alcohol-fixed, Papanicolaou-stained smears
per pass, 1 or more additional smears could be prepared
for ancillary studies by evenly distributing the aspirate ma-
terial over multiple slides. Visualization of tumor cells on
the Diff-Quik–stained smear would signify the presence
of tumor cells in the additional unstained direct smears.
We acknowledge that the continued use of needle rinses
and dedicated passes for the cell block would serve to pre-
serve the remainder of the cellular material in formalin-
fixed, paraffin-embedded form for future studies as
needed. This protocol, however, would reduce and poten-
tially eliminate the reliance solely on the cell block as a
source of cellular material for these studies. Thus, optimi-
zation of FNA specimen triage during on-site assessments
can further cement the essential role of FNA with cyto-
logic examination in the management of patients with
metastatic melanoma. In an era in which the number of
necessary ancillary studies is likely to increase, cytopatho-
logists can meet the challenge of optimally using limited
FNA material and simultaneously preventing additional
invasive procedures that could result from scenarios in
which the cell blocks exhibit insufficient cellularity.
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